ABOUT: Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. According to a a definitive agreement between the companies, Apricus Biosciences Inc - APRI - will acquire Topotarget USA, who owns Totect (Dexrazoxane HCl), the only drug approved by the FDA to treat a potentially serious complication of cancer therapy—the leakage of chemotherapy drugs from veins into surrounding tissues. This complication is known as anthracycline extravasation, and can lead to infections and tissue death. With this acquisition, Apricus Biosciences will move into the commercialization and sales of oncology and oncology supportive care pharmaceuticals. Apricus Biosciences is a revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes. Thanks for joining me and have a great day! For CRWE Newswire, Stocks to watch, I’m Shalika Jayasekera